Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Curtin

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
British Journal of Pharmacology|May 21, 2013
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancerN J Curtin
British Journal of Cancer|October 13, 2011
The role of PARP in DNA repair and its therapeutic exploitationM Javle, N J Curtin
Therapeutic Advances in Medical Oncology|November 16, 2011
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyM Javle, N J Curtin
British Journal of Cancer|October 1, 1983
Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivoN J Curtin, K Snell
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitroN J Curtin, D P Turner
Clinical and Laboratory Haematology|June 9, 2005
Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibilityN J Curtin, A P Schwarer
British Journal of Cancer|April 1, 1996
Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cellsR N Turner, N J Curtin
The Lancet. Oncology|March 22, 2002
Pemetrexed disodium, a novel antifolate with multiple targetsN J Curtin, A N Hughes
Biochemical Pharmacology|June 1, 1988
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cellsN J Curtin, A L Harris
British Journal of Cancer|July 9, 2014
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phaseP Znojek, E Willmore, N J Curtin
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
British Journal of Pharmacology|May 21, 2013
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancerN J Curtin
British Journal of Cancer|October 13, 2011
The role of PARP in DNA repair and its therapeutic exploitationM Javle, N J Curtin
Therapeutic Advances in Medical Oncology|November 16, 2011
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyM Javle, N J Curtin
British Journal of Cancer|October 1, 1983
Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivoN J Curtin, K Snell
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitroN J Curtin, D P Turner
Clinical and Laboratory Haematology|June 9, 2005
Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibilityN J Curtin, A P Schwarer
British Journal of Cancer|April 1, 1996
Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cellsR N Turner, N J Curtin
The Lancet. Oncology|March 22, 2002
Pemetrexed disodium, a novel antifolate with multiple targetsN J Curtin, A N Hughes
Biochemical Pharmacology|June 1, 1988
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cellsN J Curtin, A L Harris
British Journal of Cancer|July 9, 2014
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phaseP Znojek, E Willmore, N J Curtin
Pageof 5